The new machine learning tool, known as DeepBAR, was discovered by Xinqiang Ding, PhD, and Bin Zhang, PhD, researchers from the Massachusetts Institute of Technology in Cambridge.
Drugs are only effective if they stick to their target proteins in the body, which can slow down drug discovery. Existing techniques struggle to balance efficiency and accuracy, researchers said.
DeepBAR can accelerate the process because it is much quicker than other methods currently available.
The machine learning tool is also exact and does not make estimations like other tools.
It is anticipated to be a valuable tool for computing standard binding free energy used in drug design, the study’s authors said.
More articles on artificial intelligence:
AI could replicate, compound existing disparities in COVID-19 care, study finds
Study: Machine learning can help detect cancer cells by their acidity
Cleveland Clinic, NFL Players Association launch AI venture for neurological diseases
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
